Latest Ankylosing Spondylitis news
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
posted July 9th
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA Approves Bimzelx for Three New Indications
posted September 26th
by modernClinician Editorial Team
by modernClinician Editorial Team
Secukinumab Cuts Symptoms of Ankylosing Spondylitis
posted December 23rd
by modernClinician Editorial Team
by modernClinician Editorial Team
For patients with active ankylosing spondylitis, secukinumab is associated with reductions in symptoms at week 16, according to a study published in the Dec. 24 issue of the New England Journal of Medicine.
Editor's Recommendations
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders 
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer 
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status 
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing Related Articles
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings 
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors 
Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy 
Study IDs Neurobiological Roots of Sensory Over-Responsivity Monthly Specialist Briefings
Stay Connected
